Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.03.09.22272098: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval for the study was obtained from the South Central-Hampshire B Research Ethics Committee (20/SC/0238).
Consent: A personal or nominated consultee was identified to act on behalf of residents who lacked the capacity to consent, and written, informed consent was given by those who were able.Sex as a biological variable We adjusted for male sex (as a binary variable), age (as a cubic spline term), previous SARS-CoV2 exposure (as a binary variable), LTCF size expressed as total number of beds (as a linear term), local SARS-CoV2 incidence expressed as 7-day rolling rate per 100 population (as a linear term). Randomization not detected. Blinding not detected. Power Analysis The … SciScore for 10.1101/2022.03.09.22272098: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethical approval for the study was obtained from the South Central-Hampshire B Research Ethics Committee (20/SC/0238).
Consent: A personal or nominated consultee was identified to act on behalf of residents who lacked the capacity to consent, and written, informed consent was given by those who were able.Sex as a biological variable We adjusted for male sex (as a binary variable), age (as a cubic spline term), previous SARS-CoV2 exposure (as a binary variable), LTCF size expressed as total number of beds (as a linear term), local SARS-CoV2 incidence expressed as 7-day rolling rate per 100 population (as a linear term). Randomization not detected. Blinding not detected. Power Analysis The sample size for VIVALDI was based on the precision of estimates for antibody prevalence20 therefore, a-priori sample size calculations were not done for this analysis. Table 2: Resources
Antibodies Sentences Resources A subset of participants also consented to serum sampling to detect IgG antibodies to the SARS-CoV2 Nucleocapsid protein using the Abbott ARCHITECT system (Abbott, Maidenhead, UK) SARS-CoV2 serological test results were also linked within the COVID-19 Datastore. detect IgGsuggested: NoneSoftware and Algorithms Sentences Resources A subset of participants also consented to serum sampling to detect IgG antibodies to the SARS-CoV2 Nucleocapsid protein using the Abbott ARCHITECT system (Abbott, Maidenhead, UK) SARS-CoV2 serological test results were also linked within the COVID-19 Datastore. Abbottsuggested: (Abbott, RRID:SCR_010477)All statistical analyses were conducted using STATA 16.0. STATAsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations included the inability to distinguish hospitalisations and deaths that occurred ‘with’ rather than ‘from’ COVID-19, particularly for frail and comorbid residents, which is likely to underestimate VE; the probable significant under-ascertainment of prior exposure, particularly amongst staff, which is also likely to underestimate VE; and the possible under-ascertainment of infection events detected on LFDs without PCR confirmation, particularly amongst staff, which may overestimate VE against infection. Based on these data, and what is already known about immunity waning, we expect the reported trends to be generalisable over future rounds of vaccinations and variants. The available evidence suggests that while vaccines can induce powerful short-term immunity, this protection may quickly fade. While the risk of severe outcomes currently appears lower for the Omicron variant,31, 32 this risk is likely to increase with waning immunity, particularly for the frail LTCF resident cohort. Our data suggest that regular boosting may be required to maintain protective effects over a longer term; however, given the complex economic and political backdrop to vaccine procurement and distribution, it will be important to consider how vulnerable groups can continue to be protected against COVID-19 whilst ensuring global vaccine equity. Our findings also highlight the critical importance of ongoing surveillance in LTCF residents, to provide early warning of surges in infection asso...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title ISRCTN14447421 NA NA Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
